This article is more than 5 years old. Information may no longer be current.
Meeting Update: ASCO highlights therapeutic advances in multiple cancer subtypes
The annual ASCO Meeting, held in Chicago from June 3-7 under the theme “Collective wisdom: The future of patient-centered care and research,” featured 5 days of late-breaking clinical trials and research updates.
This HemOnc Today supplement provides readers with an overview of the most noteworthy – and potentially practice-changing – findings to be presented at the meeting. Results from one phase 3 study demonstrated that a trastuzumab biosimilar achieved outcomes comparable to those of women treated with the biosimilar’s FDA–approved reference product, and long-term follow-up of the KEYNOTE-001 study found that 40% of patients with advanced melanoma achieved 3-year OS with pembrolizumab. Perspectives from experts in the fields of hematology and oncology provide further insight into the potential implications of these results in everyday practice.
Click here to view the interactive pdf, and visit Healio.com/HemOnc for daily updates and breaking news in the specialty.
